NASDAQ:BCTX Briacell Therap (BCTX) Stock Price, News & Analysis $3.06 +0.09 (+3.03%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$3.07 +0.01 (+0.23%) As of 06/26/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Briacell Therap Stock (NASDAQ:BCTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Briacell Therap alerts:Sign Up Key Stats Today's Range$2.95▼$3.1250-Day Range$2.74▼$4.4352-Week Range$2.60▼$31.40Volume96,244 shsAverage Volume177,913 shsMarket Capitalization$26.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada. Read More Briacell Therap Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreBCTX MarketRank™: Briacell Therap scored higher than 20% of companies evaluated by MarketBeat, and ranked 788th out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBriacell Therap has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBriacell Therap has only been the subject of 1 research reports in the past 90 days.Read more about Briacell Therap's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Briacell Therap is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Briacell Therap is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBriacell Therap has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.37% of the float of Briacell Therap has been sold short.Short Interest Ratio / Days to CoverBriacell Therap has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Briacell Therap has recently decreased by 56.55%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBriacell Therap does not currently pay a dividend.Dividend GrowthBriacell Therap does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.96 News SentimentBriacell Therap has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Briacell Therap this week, compared to 2 articles on an average week.Search Interest2 people have searched for BCTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Briacell Therap to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Briacell Therap insiders have not sold or bought any company stock.Percentage Held by Insiders0.74% of the stock of Briacell Therap is held by insiders.Percentage Held by Institutions15.42% of the stock of Briacell Therap is held by institutions.Read more about Briacell Therap's insider trading history. Receive BCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Briacell Therap and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCTX Stock News HeadlinesBriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™June 25 at 7:30 AM | globenewswire.comBriacell Therap (NASDAQ:BCTX) Short Interest Up 84.6% in MayJune 17, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.June 27 at 1:00 AM | InvestorPlace (Ad)BriaCell Therapeutics Announces Closing of OfferingJune 2, 2026 | globenewswire.comBriaCell Presents Positive Clinical Data at ASCO 2026June 1, 2026 | globenewswire.comBriaCell Therapeutics Announces Pricing of OfferingMay 31, 2026 | globenewswire.comBriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast CancerMay 26, 2026 | globenewswire.comBriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026May 22, 2026 | globenewswire.comSee More Headlines BCTX Stock Analysis - Frequently Asked Questions How have BCTX shares performed this year? Briacell Therap's stock was trading at $7.11 at the beginning of 2026. Since then, BCTX shares have decreased by 57.0% and is now trading at $3.06. How were Briacell Therap's earnings last quarter? Briacell Therap (NASDAQ:BCTX) issued its earnings results on Tuesday, June, 9th. The company reported ($0.99) earnings per share for the quarter. When did Briacell Therap's stock split? Briacell Therap's stock reverse split on the morning of Tuesday, August 26th 2025.The 1-10 reverse split was announced on Tuesday, August 5th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Briacell Therap IPO? Briacell Therap (BCTX) raised $15 million in an initial public offering on Wednesday, February 24th 2021. The company issued 3,300,000 shares at a price of $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. How do I buy shares of Briacell Therap? Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Briacell Therap own? Based on aggregate information from My MarketBeat watchlists, some other companies that Briacell Therap investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Plug Power (PLUG), Micron Technology (MU) and Permian Basin Royalty Trust (PBT). Company Calendar Last Earnings6/09/2026Today6/27/2026Fiscal Year End7/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 BCTX's financial health is in the Red zone, according to TradeSmith. BCTX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCTX CIK1610820 Webwww.briacell.com Phone(604) 921-1810Fax604-921-1898Employees8Year Founded2004Profitability EPS (Trailing Twelve Months)($7.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.31 million Net MarginsN/A Pretax MarginN/A Return on Equity-153.53% Return on Assets-129.26% Debt Debt-to-Equity RatioN/A Current Ratio7.07 Quick Ratio7.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.69 per share Price / Book1.14Miscellaneous Outstanding Shares8,700,000Free Float8,636,000Market Cap$26.62 million OptionableNo Data Beta1.21 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:BCTX) was last updated on 6/27/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Briacell Therap Please log in to your account or sign up in order to add this asset to your watchlist. Share Briacell Therap With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
